

Press release Belfort, February 14, 2018

LISI ACHIEVED ONCE AGAIN EARNINGS GROWTH OBJECTIVES

- · Earnings growth:
 - o Revenue: €1.64 Bn, up €72 M (+4.6%)
 - LISI Aerospace has crossed the €1 Bn revenue mark and LISI Automotive that of €500 M;
 - Contribution of external growth transactions completed in the United States in 2016 (LISI MEDICAL Remmele) and 2017 (TERMAX) offset an unfavorable dollar effect;
 - Organic growth: +3.6%; strong in the first half (+6.1%), more limited in the second half of the year (+1.0%);
 - Operating income up by nearly €14 M (+8.9%)
 - Contribution up across all three divisions;
 - Operating margin improved by 0.4 point to 10.4%;
 - Net income stabilized at a high level (€108 M), despite a highly negative financial result (-€21.6 M) due to currency fluctuations
- Free Cash Flow highly positive despite an unfavorable currency impact (-€ 27.4 M) and a record level of capital expenditures;
- Net debt under control after the acquisition of TERMAX;
- Proposed dividend: € 0.48 per share;
- 2018 objectives: improvement in performance and strategic course maintained.

February 14, 2018 - The LISI Board of Directors met under the chairmanship of Mr. Gilles Kohler and reviewed the audited financial statements for the period ended December 31, 2017. They will be submitted for approval to the General Meeting on April 24, 2018.

| 12 months ending December 31, | | 2017 | 2016 | Changes |
|--|-------------|---------|---------|----------|
| Key elements of the in | come stat | ement | | |
| Revenue | €M | 1,643.4 | 1,571.1 | 4.6% |
| EBITDA | €M | 256.2 | 237.1 | 8.0% |
| EBITDA margin | % | 15.6 | 15.1 | 0.5 pt |
| Operating result (EBIT) | €M | 171.4 | 157.5 | 8.9% |
| Operating margin | % | 10.4 | 10.0 | 0.4 pt |
| Earnings attributable to holders of company equity | €M | 108.0 | 107.0 | 0.9% |
| Net earnings per share | € | 2.04 | 2.02 | 1.0% |
| Key elements of the cas | h flow stat | tements | | |
| Operating cash flow | €M | 203.8 | 195.8 | +€8.0 M |
| Capital expenditure, net | €M | -140.1 | -119.6 | +€20.5 M |
| Free Cash Flow* | €M | 46.3 | 73.5 | -€27.2 M |
| Key elements of the fir | nancial str | ucture | | |
| Net debt | €M | 300.2 | 218.2 | +€82.0 M |
| Ratio of net debt to equity | | 33.4% | 25.2% | +8.2 pts |

^{*} In this press release, Free Cash Flow refers to cash flow minus net industrial investments and changes in working capital requirements (WCR).

Revenue reached €1,643.4 M, an increase of €72.3 M (+4.6%), with organic growth of 3.6%.

At €1,643.4 M, consolidated revenue for fiscal 2017 were up +4.6% and reflect the following elements:

- a scope effect of €21.7 M corresponding to:
 - o a negative impact of €13.4 M or 0.8% of consolidated sales, reflecting the sale of Précimétal Fonderie de Précision (Belgium) on February 2, 2017;
 - o the €22.8 M incremental contribution, i.e. 1.4% of consolidated sales, of LISI MEDICAL Remmele, which has been integrated since May 1, 2016;
 - €12.3 M, or 0.75% of consolidated sales, brought by the integration within LISI AUTOMOTIVE of the US company TERMAX, a leading designer and manufacturer of metal and plastic clipped fastening solutions for car bodies, effective since November 1, 2017;
- an adverse effect of €10.2 M due to currency fluctuations;
- €60.8 M generated by organic growth.

| €M | LISI Consolidated | of which LISI AEROSPACE | of which LISI AUTOMOTIVE | of which LISI MEDICAL |
|--------------------------------------|----------------------|----------------------------|-----------------------------|--------------------------|
| Q1 | 444.3 | 277.6 | 128.9 | 37.9 |
| Q2 | 417.4 | 258.3 | 123.7 | 35.6 |
| Organic growth H1 2017/H1 2016 | +6.1% | +7.4% | +3.7% | +7.1% |
| Q3 | 369.7 | 222.6 | 116.2 | 31.1 |
| Q4 | 412.0 | 242.4 | 137.3 | 32.5 |
| Organic growth H2 2017/H2 2016 | +1.0% | - 1.1% | +9.6% | -8.6% |
| 2017 | 1,643.4 | 1,000.9 | 506.0 | 137.0 |

Expressed at a constant scope and exchange rates, revenue are up +3.6% (+4.6% in 2016).

Half-yearly analysis

Organic growth slowed down in the second half (+1.0%), particularly in the LISI AEROSPACE and LISI MEDICAL divisions after a sustained first half (+6.1%). The LISI AUTOMOTIVE division enjoyed good momentum.

Quarterly analysis

Compared with the same period last year, the fourth quarter posted overall organic growth of $\pm 2.8\%$, mainly driven by the "Structural Components" segment in the aerospace industry and the entire LISI AUTOMOTIVE division. Aerospace "Fasteners" and the Medical Division showed no sign of improvement over the fourth quarter of the previous year.

Divisional analysis

On a like-for-like basis and restated for the currency effect, LISI AEROSPACE's annual revenue growth stood at +3.3%. The decline of the division in the second half (-1.1%) compared to the first (+7.4%) is mainly attributable to the "Fasteners" activity in Europe: in fact, this has been negatively affected

not only by Airbus's destocking, but also by the acceleration of the dollar depreciation against the euro. In the United States, the "Fasteners" activity is picking up steam at Boeing, while the active repositioning of LISI AEROSPACE with the distribution sector is hampered by the low level of activity in business and regional aircraft. The "Structural Components" showed good momentum throughout the year, thanks in particular to the continued ramp-up of the new programs, including the LEAP engine.

Sales at the LISI AUTOMOTIVE division accelerated between the first and second half (\pm 3.6% in H1, \pm 14.4% in H2) in a European market that remained robust. The increase in revenue is particularly noticeable in the "Clipped Solutions" and "Safety Mechanical Components" segments; it reflects the gains in market share and the ramping up of new products. Revenue thus reached the historical level of \pm 506.0 M, up \pm 8.8% compared to 2016, with \pm 6.5% organic growth supported by a strong order intake for new projects at more than 10% of sales.

The LISI MEDICAL division benefited from the full year effect of the integration of LISI MEDICAL Remmele (incremental sales revenue of €22.8 M over the period). At constant scope and exchange rates, sales decreased by -2.3% with a second half-year showing a net drop (-8.6%) compared with the first (+7.1%). LISI MEDICAL Remmele had to cope with a temporary shift in the ramping up of some of its products in the field of minimally invasive surgery and was also affected by the reassignment of two significant products to other production processes.

Operating income increased by €14 M, bringing the operating margin up to 10.4%, an improvement of 0.4 point.

At \in 256.2 M, EBITDA rose by +8.0% (+ \in 19.1 M) and amounted to 15.6% of sales. The operating profit (EBIT) increased by \in 13.9 M (+8.9%) to \in 171.4 M, despite an unfavorable currency effect of -5.3 M. The operating margin reached 10.4%. Up 0.4 point from 2016, it is in line with the Group's objectives, given the evolution of its business mix.

This performance is attributable to an improvement in the operational quality across the all Group. The contribution from the productivity gains of the LEAP program (LISI Excellence Achievement Program), the gradual reorientation of the activities of the automotive division towards product ranges that yield higher margins, as well as the effects of the capital expenditure program, have been decisive. In addition, and in accordance with its commitments, the Group halved the additional costs generated in the phase of steep ramp-up of the new programs in the "Structural Components" segment. The positive productivity effects of robotics and the reduction in the cost of launching new products and should also be noted.

The year 2017 confirms the gradual rebalancing of the contribution of the three divisions. All saw their operating profit increase in value compared to the previous year. If the Aerospace Division remains the largest contributor to the consolidated operating income (75% of the Group; 78% in 2016), the Automotive Division improved its profitability to 6.6%. The Medical Division posted operating income up +€9.8 M, or 7.1% of sales.

The strongly negative impact of the financial result (- \leq 21.6 M), compared to 2016 (+ \leq 13.3 M), is explained by the following main factors:

- the financial expenses, corresponding to the cost of the long-term net debt, amounted to €5.9 M (- €5.1 M in 2016), i.e. an average fixed rate of 2.01% (1.70 % in 2016). This rate increase is offset by gains generated on current cash investments (+€2.7 M vs. +€ 0.8 M in 2016);
- the revaluation of debts and receivables mainly denominated in dollars (- €32.4 M vs. +€17.5 M in 2016). Receivables and investments in foreign currencies were mechanically affected by the sharp drop of this currency against the euro;
- the positive impact of the valuation of currency hedging instruments (+€13.9 M vs. +€0.9 M in 2016).

Non-current costs weighed down the net result for - €3.7 M (- €10.0 M in 2016) and mainly relate to consulting fees related to the relocation of the Bologne site (Haute-Marne).

The tax expense, calculated on the basis of the corporation tax as a percentage of net income before taxes, reflects an effective average rate of 26.8%, down from 33.7% in 2016. Restated from one-off items (rate change in France and the United States, additional contribution and censorship of the 3% dividend contribution in France, transition tax in the United States). The effective tax rate would be 31.1%.

At €108.0 M, net income exceeds that of 2016 (€107.0 M).

Per share, it amounts to €2.04 (€2.02 in 2016).

Based upon these results, the Group will ask the Shareholders' General Meeting to approve setting the dividend at € 0.48 per share for the 2017 financial year.

The good level of profitability achieved in 2017 largely financed the record amount of capital expenditures while generating a highly positive Free Cash Flow.

Cash flow reached €203.8 M (+€8.0 M, 12.4% of consolidated sales, compared to €195.8 M in 2016). In a context of strong growth, the Group managed to reduce its inventory again: expressed in days of sales, it decreased by 7 days compared to the 2016 financial year, a gain of nearly two weeks in two years. Through strict management discipline, customer late payment rates have been reduced, lowering consolidated working capital requirements to 74 days in 2017 (76 days in 2016).

In line with previous years, LISI continued its capital expenditures in 2017 at sustained pace: up by more than €20 M, capital expenditures represent 8.5% of sales and were mainly devoted to:

- differentiating technical initiatives across the divisions (robotization);
- initiating the last phase of the Villefranche-de-Rouergue project;
- the operational start-up of the Forge 2020 project (Bologne site);
- increase in the capacity dedicated to the manufacturing of new products.

The Group was nonetheless able to finance the capital expenditure programs while generating positive Free Cash Flow of €46.3 M despite an unfavorable currency impact of - €27.4 M.

LISI enters 2018 with a healthy financial structure

In a 2017 fiscal year marked by an unprecedented amount of investment, LISI has maintained a sound financial structure. Thus, the return on capital employed (before tax) displays good resistance: it stood at 15.0% at the end of the year, compared with 15.5% as at December 31, 2016.

The increase in net financial debt, which includes 100% of the acquisition of TERMAX¹, was limited to €82.0 M and amounted to €300.2 M as at December 31, 2017. It represents 33.4% of shareholders' equity (25.2% in 2016 and 1.2 x EBITDA).

LISI AEROSPACE

- The billion euro revenue mark is crossed for the first time, with a strong disparity in organic growth between the first (+7.4%) and the second (-1.1%) half of the year;
- Improvement of all the management indicators versus the prior year, with a sharp contrast
 between the first and second half of the year, the latter being affected by the temporary
 adjustment of Airbus inventories and the adverse effect related to the decline of the dollar
 against the euro;
- Positive Free Cash Flow after a sharp increase in capital expenditures (+11.0%);
- Challenging start to 2018 in line with the second half of 2017.

¹ It should be recalled that the acquisition of TERMAX was structured in two stages: as a first step, the shareholders of TERMAX Corporation sold 51% of the capital to LISI AUTOMOTIVE for approximately €51 M. While the LISI Group is expected to acquire the balance of the capital by 2020, it has decided to recognize as of December 31, 2017 the entire corresponding debt, i.e. approximately €123 M.

| | 2017 | 2016 | Change |
|----------------------|---------|-------|---|
| | | | +3.3% |
| Revenue (in € M) | 1,000.9 | 987.2 | On a constant scope and exchange rate basis |
| Operating profit | 128.1 | 122.9 | +4.2% |
| As a % of revenue | 12.8% | 12.4% | +0.4 pt |
| Free Cash Flow (€ M) | 61.6 | 32.3 | +€29.3 M |
| As a % of revenue | 6.2% | 3.3% | +2.9 pts |

LISI AUTOMOTIVE

- Revenue exceeded €500 M for the first time;
- New increase in order intake for new products and accelerated growth in international markets;
- 5th consecutive year of improvement in operating margin, reflecting the strategy of changing the product mix towards more value-added products;
- positive Free Cash Flow for the second year in a row, with significant improvement compared to 2016;
- Good visibility over fiscal year 2018, driven by new products and by the full-year benefits from TERMAX's contribution.

| | 2017 | 2016 | Change |
|----------------------|-------|-------|---|
| Revenue (in € M) | 506.0 | 465.3 | +6.5% On a constant scope and exchange rate basis |
| Operating profit | 33.3 | 26.3 | +26.6% |
| As a % of revenue | 6.6% | 5.7% | +0.9 pt |
| Free Cash Flow (€ M) | 13.1 | 7.9 | +€5.2 M |
| As a % of revenue | 2.6% | 1.7% | +0.9 pt |

LISI MEDICAL

- The Division's performance is impaired by a very unfavorable volume effect in the second half at LISI MEDICAL Remmele as well as by an increase in medical care expenses;
- Increase in operating income in value;
- Further growth in Free Cash Flow with a doubling of investments compared to 2016;
- Continued drop in inventories reaching the historically low level of 61 days;
- Gradual ramp-up of new projects expected in 2018.

| | 2017 | 2016 | Change |
|----------------------|-------|-------|--|
| Revenue (in € M) | 137.0 | 119.1 | -2.3% On a constant scope and exchange rate basis |
| Operating profit | 9.8 | 9.3 | +5.7% |
| As a % of revenue | 7.1% | 7.8% | -0.7 pt |
| Free Cash Flow (€ M) | 6.7 | 3.7 | +€3.0 M |
| As a % of revenue | 4.9% | 3.1% | +1.8 pt |

OUTLOOK

Challenges will abound in 2018:

- LISI AEROSPACE: the completion of numerous challenging projects, including the relocation of the Polish site dedicated to the finishing of blades, the further reduction in the additional costs of industrialization, compliance with the delivery programs in the "Structural Components" segment, the adaptation to a slower activity in "Fasteners" in Europe with a significant impact expected for the first part of the year;
- LISI AUTOMOTIVE: the industrial materialization of new orders, the extension of the Czech site specializing in the production of safety mechanical components, the "Delle of the Future" project, the effective ability to pass higher raw materials costs into selling prices;
- LISI MEDICAL: back to overall growth.

The Group is fully committed to achieving a double-digit current operating income, a positive Free Cash Flow and a growth in value of its operating indicators, in a context of currency volatility. The pursuit and deployment of many structuring industrial projects (robotization and productivity improvement, innovation), the launch of the first initiatives in the field of the digitization of production, all aim at providing technological lead to consolidate its [competitive] differentiation in a sustainable manner in well-oriented markets over time.

Contact

Emmanuel Viellard Tel: +33 (0)3 84 57 00 77

Email: emmanuel.viellard@lisi-group.com

Website: www.lisi-group.com

The next announcements will appear after close of trading on Paris Euronext

Shareholders' General Meeting: April 24, 2018 Q1 2018 financial information: April 25, 2018

H1 2018 results: July 25, 2018

Q3 2018 financial Information: October 24, 2018

The LISI share is listed on Euronext, compartment A and belongs to the CAC® AERO & DEF., CAC® All Shares, CAC® Industrials indices, under the ISIN code: FR 0000050353. LISI is a worldwide leading manufacturer of fasteners and assembly components for the Aerospace, Automotive, and medical implants industries.

Reuters:GFII.PA Bloomberg:FII FP

LISI Group consolidated balance sheet

ASSETS

| (in €'000) | 31/12/2017 | 31/12/2016 |
|--|---|--|
| LONG-TERM ASSETS | | |
| Goodwill Other intangible assets Tangible assets Long-term financial assets Deferred tax assets Other long-term assets | 321 377 30 177 619 593 9 982 8 568 429 | 300 426 23 822 570 877 9 481 19 075 950 |
| Total long-term assets | 990 126 | 924 631 |
| SHORT-TERM ASSETS | | |
| Inventories Taxes – Claim on the state Trade and other receivables Cash and cash equivalents | 337 099 41 269 261 249 197 576 | 338 986 6 772 260 416 141 719 |
| Total short-term assets | 837 193 | 747 894 |
| TOTAL ASSETS | 1 827 319 | 1 672 525 |

TOTAL EQUITY AND LIABILITIES

| (in €'000) | 31/12/2017 | 31/12/2016 |
|---|--|--|
| SHAREHOLDERS' EQUITY | | |
| Share capital Additional paid-in capital Treasury shares Consolidated reserves Conversion reserves Other income and expenses recorded directly as shareholders' equity Profit (loss) for the period | 21 610 72 584 (14 720) 688 882 8 419 5 261 107 965 | 21 610 72 584 (14 610) 659 375 27 742 (13 452) 107 008 |
| Total shareholders' equity - Group's share | 890 001 | 860 258 |
| Minority interests | 7 664 | 4 964 |
| Total shareholders' equity | 897 665 | 865 222 |
| LONG-TERM LIABILITIES | | |
| Long-term provisions Non-current financial debts Other long-term liabilities Deferred tax liabilities | 64 995 317 757 11 605 40 747 | 70 474 253 856 12 392 33 376 |
| Total long-term liabilities | 435 104 | 370 098 |
| SHORT-TERM LIABILITIES | | |
| Short-term provisions Short-term borrowings ¹ Trade and other accounts payable Taxes due | 15 156 179 973 297 109 2 312 | 23 174 106 037 304 492 3 503 |
| Total short-term liabilities | 494 550 | 437 206 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 1 827 319 | 1 672 525 |
| ¹ Of which banking facilities | 16 441 | 15 984 |

LISI Group consolidated income

| (in €'000) | 31/12/2017 | 31/12/2016 |
|--|--|--|
| Pre-tax sales | 1 643 356 | 1 571 104 |
| Changes in stock, finished products and production in progress | (884) | (1 519) |
| Total production Other revenues (a) | 1 642 472 26 661 | 1 569 585 23 777 |
| Total operating revenues | 1 669 133 | 1 593 362 |
| Consumed goods Other purchases and external expenses Taxes and duties (b) Personnel expenses (including temporary employees) (c) | (443 119) (338 332) (12 171) (619 333) | (414 436) (325 957) (11 353) (604 484) |
| EBITDA | 256 178 | 237 132 |
| Depreciation Net provisions | (90 132) 5 352 | (80 872) 1 200 |
| EBIT | 171 398 | 157 460 |
| Non-recurring operating expenses Non-recurring operating revenues | (7 329) 3 649 | (12 950) 2 974 |
| 3 - 1 - 1 - 3 - 1 - 1 - 1 - 1 - 1 - 1 - | 0 0-10 | 2 31 4 |
| Operating profit | 167 718 | 147 483 |
| | | |
| Operating profit | 167 718 | 147 483 |
| Operating profit Financing expenses and revenue on cash Revenue from cash Financing expenses Other interest revenue and expenses Other financial items | 167 718 (2 421) 3 445 (5 866) (19 166) 60 852 | 147 483 (4 420) 1 146 (5 566) 17 770 55 409 |
| Operating profit Financing expenses and revenue on cash Revenue from cash Financing expenses Other interest revenue and expenses Other financial items Other interest expenses | 167 718 (2 421) 3 445 (5 866) (19 166) 60 852 (80 018) (39 182) | 147 483 (4 420) 1 146 (5 566) 17 770 55 409 (37 639) |
| Operating profit Financing expenses and revenue on cash Revenue from cash Financing expenses Other interest revenue and expenses Other financial items Other interest expenses Taxes (of which CVAE (Tax on Companies' Added Value)) (b) | 167 718 (2 421) 3 445 (5 866) (19 166) 60 852 (80 018) (39 182) | 147 483 (4 420) 1 146 (5 566) 17 770 55 409 (37 639) (54 443) |
| Coperating profit Financing expenses and revenue on cash Revenue from cash Financing expenses Other interest revenue and expenses Other financial items Other interest expenses Taxes (of which CVAE (Tax on Companies' Added Value)) (b) Share of net income of companies accounted for by the equity method | 167 718 (2 421) 3 445 (5 866) (19 166) 60 852 (80 018) (39 182) | 147 483 (4 420) 1 146 (5 566) 17 770 55 409 (37 639) (54 443) |
| Profit (loss) for the period Financing profit Financing expenses and revenue on cash Revenue from cash Financing expenses Other interest revenue and expenses Other financial items Other interest expenses Taxes (of which CVAE (Tax on Companies' Added Value)) (b) Share of net income of companies accounted for by the equity method Profit (loss) for the period attributable as company shareholders' equity | 167 718 (2 421) 3 445 (5 866) (19 166) 60 852 (80 018) (39 182) 0 106 951 | 147 483 (4 420) 1 146 (5 566) 17 770 55 409 (37 639) (54 443) 0 106 390 |

LISI Group consolidated cash flow table

| Operating activities Net earnings Elim. of the income of companies accounted for by the equity method Elimination of net expenses not affecting cash flows: - Depreciation and non-recurrent financial provisions - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax Taxes paid | 31/12/2017 106 951 89 819 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 31/12/2016 106 390 81 232 6 059 911 194 592 1 213 195 805 48 385 |
|--|--|--|
| Net earnings Elim. of the income of companies accounted for by the equity method Elimination of net expenses not affecting cash flows: - Depreciation and non-recurrent financial provisions - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 89 819 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 81 232 6 059 911 194 592 1 213 195 805 48 385 |
| Elim. of the income of companies accounted for by the equity method Elimination of net expenses not affecting cash flows: - Depreciation and non-recurrent financial provisions - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 89 819 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 81 232 6 059 911 194 592 1 213 195 805 48 385 |
| Elim. of the income of companies accounted for by the equity method Elimination of net expenses not affecting cash flows: - Depreciation and non-recurrent financial provisions - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 6 059 911 194 592 1 213 195 805 48 385 |
| - Depreciation and non-recurrent financial provisions - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 6 059 911 194 592 1 213 195 805 48 385 |
| - Depreciation and non-recurrent financial provisions - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 6 059 911 194 592 1 213 195 805 48 385 |
| - Changes in deferred taxes - Income on disposals, provisions for liabilities and others Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 10 335 (1 932) 205 173 (1 335) 203 838 28 847 5 686 67 | 6 059 911 194 592 1 213 195 805 48 385 |
| Gross cash flow margin Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 205 173 (1 335) 203 838 28 847 5 686 67 | 194 592 1 213 195 805 48 385 |
| Net changes in provisions provided by or used for current operations Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | (1 335) 203 838 28 847 5 686 67 | 1 213 195 805 48 385 |
| Operating cash flow Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 203 838 28 847 5 686 67 | 195 805 48 385 |
| Income tax expense (revenue) Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 28 847 5 686 67 | 48 385 |
| Elimination of net borrowing costs Effect of changes in inventory on cash Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | 67 | |
| Effect of changes in accounts receivable and accounts payable Net cash provided by or used for operations before tax | | 5 782 |
| Net cash provided by or used for operations before tax | 47.070 | 2 504 |
| • | 17 973 | (23 729) |
| | 256 411 (64 298) | 228 747 (29 807) |
| · · | | , |
| Cash provided by or used for operations (A) | 192 113 | 198 938 |
| Investment activities | | |
| Acquisition of consolidated companies | (51 014) | (92 136) |
| Cash acquired | 2 409 | (1 973) |
| Acquisition of tangible and intangible fixed assets | (141 694) | (132 609) |
| Acquisition of financial assets Change in granted loans and advances | (722) | (746) |
| Investment subsidies received | (722) | (746) |
| Dividends received | | |
| Total cash used for investment activities | (191 021) | (227 463) |
| Divested cash | (5 701) | 36 |
| Disposal of consolidated companies | 13 060 | 40.005 |
| Disposal of tangible and intangible fixed assets Disposal of financial assets | 1 548 | 12 995 |
| Total cash from disposals | 8 907 | 13 031 |
| Cash provided by or used for investment activities (B) | (182 114) | (214 434) |
| Financing activities | | |
| · · · · · · · · · · · · · · · · · · · | | |
| Capital increase Net disposal (acquisition) of treasury shares | 1 920 | 32 |
| Dividends paid to shareholders of the Group | (23 873) | (20 629) |
| Dividends paid to minority interests of consolidated companies | (20010) | (20 023) |
| Total cash from equity operations | (21 954) | (20 598) |
| Issue of long-term loans | 50 913 | 88 376 |
| Issue of short-term loans | 126 640 | 52 028 |
| Repayment of long-term loans Repayment of short-term loans | 1 372 (102 807) | (35 309) |
| Net interest expense paid | (5 680) | (45 143) (5 782) |
| rtot interest expense paia | 70 439 | 54 171 |
| Total cash from operations on loans and other financial liabilities | | |
| Total cash from operations on loans and other financial liabilities Cash provided by or used for financing activities (C) | 48 485 | 33 573 |
| Cash provided by or used for financing activities (C) | | |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) | (2 976) | (8 149) |
| Cash provided by or used for financing activities (C) | | |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) | (2 976) | (8 149) |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) Effect of adjustments in treasury shares (D) * Changes in net cash (A+B+C+D) | (2 976) (110) 55 398 | (8 149) (762) 9 166 |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) Effect of adjustments in treasury shares (D) * Changes in net cash (A+B+C+D) Cash at January 1st (E) | (2 976) (110) | (8 149) (762) |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) Effect of adjustments in treasury shares (D) * Changes in net cash (A+B+C+D) | (2 976) (110) 55 398 125 736 | (8 149) (762) 9 166 116 569 |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) Effect of adjustments in treasury shares (D) * Changes in net cash (A+B+C+D) Cash at January 1st (E) Cash at year end (A+B+C+D+E) Cash and cash equivalents | (2 976) (110) 55 398 125 736 181 134 197 575 | (8 149) (762) 9 166 116 569 125 735 141 719 |
| Cash provided by or used for financing activities (C) Effect of change in foreign exchange rates (D) Effect of adjustments in treasury shares (D) * Changes in net cash (A+B+C+D) Cash at January 1st (E) Cash at year end (A+B+C+D+E) | (2 976) (110) 55 398 125 736 181 134 | (8 149) (762) 9 166 116 569 125 735 |

Change in LISI Group consolidated shareholders' equity

| (in €'000) | Share | Capital-linked premiums | Treasury | Consolidated | Conversion | Other income and expenses recorded directly as shareholders' equity | Profit for the period, group share | Group's share of shareholders' equity | Minority interests | Total shareholders' equity |
|---|--------|----------------------------|----------|--|----------------|---|------------------------------------|---|---------------------------|---|
| Shareholders' equity at January 1, 2016 | 21 610 | 72 584 | (14 740) | 603 092 | 30 598 | (2 652) | 81 764 | 792 257 | 1 189 | 793 445 |
| Profit (loss) for the period N (a) Translation differential (b) Payments in shares (c) Capital increase Restatements of treasury shares (d) Restatements as per IAS19 (g) Appropriation of N-1 earnings | 0 | 0 | 130 | 1 604 | (2 856) | 95 (3 519) | 107 008 | 107 008 (2 856) 1 604 0 225 (3 519) | (18) | 106 389 (2 874) 1 604 3 947 225 (3 519) 0 |
| oriange in scope Dividends distributed Reclassification Restatements of financial instruments (f) Various (e) | | | | (20 629) | | (8 980) | | (20 629) 0 (8 980) (4 852) | (48) | (20 629) 0 (9 028) (4 852) |
| Shareholders' equity at December 31, 2016 including total revenues and expenses posted for the period $(a) + (b) + (c) + (d) + (e) + (f)$ | 21 610 | 72 584 | (14 610) | 626 099 | 27 742 (2 856) | (15 056) | 107 008 | 860 258 | 4 964 (685) | 865 222 |
| Shareholders' equity as at January 1, 2017 | 21 610 | 72 584 | -14 610 | 659 375 | 27 742 | -13 452 | 107 008 | 860 258 | 4 964 | 865 222 |
| Profit (loss) for the period N (a) Translation differential (b) Payments in shares (c) Capital increase Restatements of treasury shares (d) Restatements as per IAS19 (g) Appropriation of N-1 earnings Change in scope Dividends distributed | 0 | 0 | (110) | 2 075 107 008 (57 244) (23 872) | (19 324) | 156 369 | 107 965 | 107 965 (19 324) 2 075 0 46 369 0 (57 244) (23 872) | (1014) 73 2000 0 | 106 951 (19 251) 2 075 2 000 46 369 0 (57 244) (23 872) |
| Neclassification Restatements of financial instruments (f) Various (e) Shareholders' equity at December 31, 2017 | 21 610 | 72 584 | (14 720) | 1 540 | 8 419 | 18 188 | 107 965 | 18 188 1540 | 86 1 556 7 664 | 18 274 3 096 897 665 |
| including total revenues and expenses posted for the period $(a) + (b) + (c) + (d) + (e) + (f) + (g)$ | | | | | (19 324) | 18 713 | 107 965 | | (855) | 106 500 |